Asian press release distribution

Press Releases for Friday, August 19, 2022

晶门半导体公布2022年中期业绩：销售额增长45.1%至108.5百万美元 20:52 HKT/SGT

晶門半導體公佈2022年中期業績：銷售額增長45.1%至108.5百萬美元 20:51 HKT/SGT

Solomon Systech Announces 2022 Interim Results: Revenue Increased by about 45.1% to US$108.5 Million in 1H 2022 20:50 HKT/SGT

Prizes, Happy Hour Awaits Participants of #DXLeadersPH2022 19:58 HKT/SGT

New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% 19:51 HKT/SGT

冠君产业信托公布2022年度中期业绩 18:12 HKT/SGT

冠君產業信託公布2022年度中期業績 18:11 HKT/SGT

Champion REIT Announces 2022 Interim Results 18:10 HKT/SGT

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY 17:55 HKT/SGT

LEXUS、モントレー・カー・ウィーク2022でNEXT CHAPTERモデルを出展 16:00 HKT/SGT

台灣精品於 2022 年新加坡國際醫療展首次亮相展出10 家醫療科技暨照護領域的創新企業 14:01 HKT/SGT

台灣精品於 2022 年新加坡國際醫療展首次亮相展出10 家醫療科技暨照護領域的創新企業 14:01 HKT/SGT

Taiwan Excellence Pavilion to showcase 10 leading medical tech innovators at Medical Fair Asia 2022 14:00 HKT/SGT

Taiwan Excellence Pavilion to showcase 10 leading medical tech innovators at Medical Fair Asia 2022 14:00 HKT/SGT

港股稀缺标的百奥赛图今日开启招股 11:41 HKT/SGT

港股稀缺標的百奧賽圖今日開啟招股 11:40 HKT/SGT

Sirnaomics核心产品RNAi治疗药物STP705用于治疗面部原位鳞状细胞皮肤癌的I/II期临床试验完成首例受试者给药 11:32 HKT/SGT

Sirnaomics核心產品RNAi治療藥物STP705用於治療面部原位鱗狀細胞皮膚癌的I/II期臨床試驗完成首例受試者給藥 11:31 HKT/SGT

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ 11:30 HKT/SGT

顺丰同城H股全流通申请获中国证监会正式批准业内：有利于改善流动性和成交量 10:32 HKT/SGT

順豐同城H股全流通申請獲中國證監會正式批准業內：有利於改善流動性和成交量 10:31 HKT/SGT

After 500 per cent spike in a single day, MuskMelon NFT advances its game for yielding higher returns 08:00 HKT/SGT

ACN Search:

Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575